Immunotherapy may treat skin cancer in kidney transplant patients without rejection
NCT ID NCT07715734
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This trial investigates whether the immunotherapy drug cemiplimab can shrink advanced cutaneous squamous cell carcinoma in people who have received a kidney transplant. Because immunotherapy can trigger organ rejection, participants also receive the steroid prednisone to protect the transplanted kidney. The study aims to see if this approach can fight the cancer while keeping the kidney safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cemiplimab (an immunotherapy drug) given with prednisone (a steroid to protect the transplanted kidney)
- What this could lead to
- If successful, this could offer a new treatment option for kidney transplant recipients with advanced skin cancer, a group often excluded from immunotherapy due to rejection risk.
- What could go wrong
- This is a small, early-phase trial, so results may not apply broadly. The combination of immunotherapy and steroids may still cause kidney rejection or other serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may take the guesswork out of transplant drug dosing
- Could a daily pill shield transplant patients from a common virus?
- Can a Home-Based program help kidney patients get stronger before transplant?
- Gene expression platform could revolutionize kidney transplant rejection diagnosis
- Blood clot marker may predict immunotherapy success in advanced skin cancer
- Could a common diabetes drug stop diabetes after kidney transplant?